RT Journal Article
T1 A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases
A1 Martínez Mora, María Del Carmen
A1 Juarranz Moratilla, Yasmina
A1 Gutiérrez Cañas, Irene
A1 Carrión Caballo, Mar
A1 Pérez García, Selene
A1 Villanueva Romero, Raúl
A1 Castro Vázquez, David
A1 Lamana Domínguez, Amalia
A1 Mellado, Mario
A1 González Álvaro, Isidoro
A1 Pérez Gomáriz, Rosa María
AB The neuroendocrine and immune systems are coordinated to maintain the homeostasis of the organism, generating bidirectional communication through shared mediators and receptors. Vasoactive intestinal peptide (VIP) is the paradigm of an endogenous neuropeptide produced by neurons and endocrine and immune cells, involved in the control of both innate and adaptive immune responses. Exogenous administration of VIP exerts therapeutic effects in models of autoimmune/inflammatory diseases mediated by G-protein-coupled receptors (VPAC1 and VPAC2). Currently, there are no curative therapies for inflammatory and autoimmune diseases, and patients present complex diagnostic, therapeutic, and prognostic problems in daily clinical practice due to their heterogeneous nature. This review focuses on the biology of VIP and VIP receptor signaling, as well as its protective effects as an immunomodulatory factor. Recent progress in improving the stability, selectivity, and effectiveness of VIP/receptors analogues and new routes of administration are highlighted, as well as important advances in their use as biomarkers, contributing to their potential application in precision medicine. On the 50th anniversary of VIP’s discovery, this review presents a spectrum of potential clinical benefits applied to inflammatory and autoimmune diseases.
PB MDPI
SN 1422-0067
YR 2019
FD 2019-12-20
LK https://hdl.handle.net/20.500.14352/6408
UL https://hdl.handle.net/20.500.14352/6408
LA eng
NO Instituto de Salud Carlos III (ISCIII)
NO Ministerio de Economía y Competitividad (MINECO)/FEDER
DS Docta Complutense
RD 7 abr 2025